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a  b  s  t  r  a  c  t
Soon  after  HIV  was  discovered  as  the  cause  of  AIDS  in  1983–1984,  there  was  an  expectation  that  a  pre-
ventive vaccine  would  be rapidly  developed.  In trying  to achieve  that  goal,  three  successive  scientiﬁc
paradigms  have  been  explored:  induction  of  neutralizing  antibodies,  induction  of  cell mediated  immu-
nity, and  exploration  of  combination  approaches  and  novel  concepts.  Although  major  progress  has  been
made in  understanding  the  scientiﬁc  basis  for  HIV  vaccine  development,  efﬁcacy  trials  have  been crit-eywords:
IV
IDS
istory
accines
ical in  moving  the  ﬁeld  forward.  In  2009,  the  ﬁeld  was  reinvigorated  with  the  modest  results  obtained
from the  RV144  trial  conducted  in Thailand.  Here,  we  review  those  vaccine  development  efforts,  with  an
emphasis  on events  that  occurred  during  the  earlier  years.  The  goal  is  to  provide  younger  generations  of
scientists  with  information  and  inspiration  to  continue  the  search  for  an  HIV  vaccine.
© 2013 The Author. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 
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. Introduction
Soon after the human immunodeﬁciency virus (HIV) was iso-
ated and conﬁrmed as the cause of AIDS in 1983–1984 [1,2] it
as widely expected that an effective vaccine would be rapidly
eveloped. Thirty years have passed and we are still struggling to
evelop an elusive vaccine [3,4]. The goal of this review is to out-
ine the major insights that have guided past efforts. Although the
cience underpinning the HIV vaccine effort is discussed, this is not
ntended to be a scientiﬁc review. It is rather an historical analy-
is informed by personal experience derived from more than 25
ears of work on the subject, ﬁrst at the World Health Organiza-
ion (WHO), and currently at the Bill & Melinda Gates Foundation
5–14].
. Initial optimism (1984–1986)
.1. “A vaccine in two years”
In 1984 the US Secretary of Health and Human Services, Mar-
aret Heckler, declared that “a vaccine (will be) ready for testing
n approximately two  years” [3]. Cautious optimism was  also
xpressed by others. The US Assistant Secretary of Health, Edward
randt, acknowledged that “nobody knows for certain how long it
ill take to develop the vaccine, although the general speculation
s that it will be available for clinical testing within two  or three
ears” [15]. Don Francis, then at the US Centers for Disease Control
CDC), in one of the ﬁrst papers discussing prospects for a future HIV
accine, expressed optimism based on the recent development of
 vaccine for feline leukemia virus, another retrovirus causing an
IDS-like disease in cats [16]. However, no one knew at time that
IV/AIDS was much more complex than any other viral disease for
hich vaccines have been successfully developed [13].
.2. The promise of modern biology
Although most current viral vaccines are based on either live-
ttenuated or whole-inactivated viruses, these approaches were
enerally considered unsafe for an HIV vaccine because of the dan-
er of integration of the proviral DNA in the host chromosome
17]. New recombinant DNA technologies were booming during the
id-1980s, and these technologies were seen as the most practi-
al approach to develop a safe and effective HIV vaccine. A recent
recedent was hepatitis B for which a plasma derived vaccine had
een licensed by the US Food and Drug Administration (FDA) in
981. Although it was highly effective, concerns were raised that
he source of the vaccine antigen was the plasma of individu-
ls who could also be carrying the AIDS virus. The solution came
hen the surface antigen of the hepatitis B virus was successfully
loned and expressed in yeast, allowing for the manufacturing of a
ew recombinant hepatitis B vaccine which was licensed in 1986
18,19].
Following the hepatitis B model, the HIV scientiﬁc community
avored the development of a subunit vaccine based on genetically
ngineered antigens representing the outer envelope glycopro-
eins of HIV [20]. Perhaps the ﬁrst attempt to organize a systematic
earch for an HIV vaccine occurred as early as 1984 when Robert . . . .  .  .  .  .  .  . . . .  .  .  .  .  .  . . .  . .  .  .  .  . . . . . .  .  .  .  . . . . . . .  .  .  . . . .  . .  .  . .  . .  .  .  . .  .  .  .  .  . . . .  . .  .  .  . . 3512
Gallo established an informal international collaborative network
known as HIVAC, with an initial focus on envelope-based vaccines
[21]. In 1986, Anthony Fauci, who had been appointed in 1984
as the Director of the National Institute of Allergy and Infectious
Diseases (NIAID), reported that virus subunits, synthetic peptides
and vaccinia-vectored vaccines were already being explored in
small animals. Nevertheless, Fauci cautiously raised the issue of
whether an effective vaccine would even be possible, recognizing
the lack of information of what could constitute a protective
immune response [22].
The initial vaccine effort was  beneﬁting from rapid advances in
the molecular biology of HIV that occurred in the following ﬁve
years after its discovery. These advances include the identiﬁcation
of the major structural proteins of the virus [23] and the cloning
and sequencing of the HIV genome [24]. Early information on the
genetic variability of different HIV strains heralded one of the great-
est challenges that would thwart HIV vaccine development for
years [25]. Neutralizing antibodies were described in 1985 [26],
although their protective efﬁcacy was not evident since titers were
similar among asymptomatic carriers and patients with the dis-
ease. Moreover, as early as 1988, it was recognized by the group of
Jay Levy, from the University of California in San Francisco, that dif-
ferent HIV strains may  belong to different neutralization subtypes
[27].
Rapid progress was also made on the development of potential
non-human primate (NHP) models for HIV infection and vac-
cine development. Experimental HIV infection of chimpanzees was
achieved in 1984 [28,29] and in 1985 the ﬁrst simian immunodeﬁ-
ciency virus (SIV) was  isolated [30].
3. The ﬁrst HIV vaccine trial in the world: 1986
The 1984 prediction of Secretary Heckler became a reality due
to the audacity of Daniel Zagury, from the Pierre and Marie Curie
University in Paris. In 1987, Zagury and collaborators reported
that in November 1986 they initiated a phase I human trial in
Zaire (now the Democratic Republic of Congo) [31]. Recogniz-
ing the potential variability of HIV, Zagury used a vaccinia vector
expressing gp160, the envelope glycoprotein of the virus. With
this approach Zagury hoped that the vaccine would induce both,
antibodies capable of neutralizing virus strains closely related to
the one included in the vaccine, as well as cytotoxic T lympho-
cytes (CTL) “that might overcome the limitations of type-speciﬁc
responses to potential immunogens.” The paper described the
results from the vaccination of Zagury himself, who reportedly
was  the ﬁrst person to receive the vaccine. It also mentions
that preliminary conﬁrmation of those results came from addi-
tional immunization “of a small group of Zairians.” In 1988,
Zagury and collaborators also reported the use of gp160 to boost
the vaccinia-induced immune response [32]. Interestingly, this
poxvirus-prime/protein-boost protocol was  not signiﬁcantly dif-
ferent from the one used in the modestly successful Thai RV144
trial 16 years later [33].
In addition, Zagury and French collaborators also explored, in
1990, the therapeutic potential of HIV vaccines, administering to
HIV-infected patients formalin inactivated autologous cells that
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ad been previously infected ex vivo with a vaccinia vector express-
ng several HIV genes [34].
These pioneering efforts from Zagury, with both a preventive
rime-boost approach and with a therapeutic vaccine, have almost
ut disappeared from the collective memory. The reasons are two-
old. In 1991, it was revealed in the media that the “small group
f Zairians” who participated in the trial was in fact a group of
oung children. This led to accusations of unethical behavior from
hich Zagury was eventually exonerated. To make things worse,
hree of the volunteers who participated in the therapeutic vac-
ine trial, which was basically a compassionate trial in patients
ith advanced disease, died from possible complications related
o disseminated infection with the vaccinia vector [35].
As Jon Cohen put it, “ultimately the trial went nowhere and
as widely criticized for being run without the international com-
unity’s knowledge, involving children, and using unapproved
aterials for the vaccine” [3]. Cohen concluded that these trials
put AIDS vaccine researchers on notice that the ethics of the tri-
ls they stage, especially in poor countries, would receive intense
crutiny.”
. Three overlapping “waves” of HIV vaccine paradigms and
linical trials
Despite many scientiﬁc uncertainties, a wide variety of candi-
ate vaccines have been developed in the last 30 years, and the
ost promising have moved to clinical trials in humans.
The HIV vaccine pipeline has continuously evolved, passing
hrough three main waves of vaccine development paradigms
9,11]: (1) induction of neutralizing antibodies, (2) induction of
TL responses, and (3) combinations of different immune responses
Fig. 1).
These vaccine waves have been overlapping and not strictly
equential. The overlap explains some of the disagreements that
ave plagued the ﬁeld, with proponents of new paradigms chal-
enging the previous ones, even before the ﬁeld has had an
pportunity to fully test them in properly conducted clinical trials.
An analysis of the clinical trials database from the International
IDS Vaccine Initiative (IAVI) indicates that a total of 218 clini-
al trials have been conducted since 1988, most of which have
een categorized as early phase I safety/immunogenicity trials [36].
he majority of these trials involved different prime-boost com-
inations, followed in frequency by proteins or peptides, poxvirus
ectors, DNA vaccines, adenovirus vectors, and other concepts. Only
ve vaccines have moved to phase IIb/III efﬁcacy trials [37,38].
he majority of these trials (approximately 140) have been imple-
ented in the United States, although, many have been done in
ther countries, including developing countries. Thailand has been
he most active, having implemented two of the ﬁve efﬁcacy trials
ave been conducted thus far [39,40].
Fig. 1. Evolution of HIV vaccine p013) 3502– 3518
5. First wave of HIV vaccine trials: induction of neutralizing
antibodies (1988–2003)
We  propose that this wave started with the ﬁrst HIV vaccine
trial conducted in the US in 1988, and ended in 2003 with the neg-
ative results from the efﬁcacy trials of the VaxGen gp120 candidate
vaccines [41,42].
5.1. Envelope glycoprotein vaccines
The initial HIV vaccines were based on the concept that neutral-
izing antibodies would be sufﬁcient to confer protection against
HIV infection. After all, most existing vaccines work through anti-
bodies that block infection or interfere with systemic infection
[43]. Most of those early HIV vaccines were based on the enve-
lope glycoproteins of the virus (mainly gp120 or gp160), which
are responsible for virus binding to the target cells, and serve as
the main target for the neutralizing antibodies. The demonstration
in 1987 that HIV envelope glycoproteins, either puriﬁed from viri-
ons or produced by recombinant technology, were safe and capable
of inducing neutralizing antibodies in non-human primates (NHP),
provided the scientiﬁc basis for the ﬁrst clinical trials [44,45].
The ﬁrst HIV vaccine trial conducted in the US evaluated a
recombinant form of the envelope glycoprotein gp160 produced
in a baculovirus-insect cell system. The product, named VaxSyn®,
was  manufactured by MicroGeneSys (Meridien, CT). The trial was
approved by the FDA in September 1987 and the actual trial started
in February 1988 [46]. The trial showed that the vaccine was safe
and that it induced binding antibodies, although no signiﬁcant neu-
tralizing antibodies were generated [47].
Other envelope constructs rapidly followed through, especially
gp120 and gp160 molecules produced in yeast or mammalian
cell systems, with the main candidates manufactured by Chi-
ron/Biocene (Emeryville, CA), Genentech (South San Francisco, CA),
Immune AG (Vienna, Austria) and Pasteur Merieux/Connaught)
[48–53]. Between 1988 and 2003, at least 35 phase I trials
were conducted with different envelope proteins. The results
showed that, in general, the native glycosylated molecules pro-
duced in mammalian cells were safe and immunogenic, inducing
binding and neutralizing antibodies. These vaccines also primed
CD4+ cells, but were generally ineffective in inducing CD8+ CTL
responses.
5.2. Vaccinia vectors and prime-boost regimes
The induction of CTL responses, which was already perceived
as a desirable characteristic of an HIV vaccine, could be achieved
through the use of live vectors, especially poxvirus vectors [54].
Live vectors were very appealing because they could present anti-
gens to the immune system simulating natural infection. In 1986,
two  different groups reported the expression of the HIV envelope
aradigms and clinical trials.
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ene in vaccinia vectors [55,56] and in November 1988 one of these
onstructs was the second candidate vaccine to enter clinical trials
n the US. The vaccine, HIVAC-1e®, which expressed gp160, was
anufactured by Bristol Myers-Squibb/Oncogen (Seattle, WA)  and
t had been found to be immunogenic in chimpanzees, although
t failed to prevent infection after challenge [57]. In humans, the
accine was found to induce strong T-cell responses, although
hese responses were transient and no antibodies against HIV were
etected [58]. Another vaccinia vector produced by Therion Biolo-
ics Corporation (Cambridge, MA), expressing the env and gag/pol
enes, entered clinical trials in 1994 [59].
An important early insight was that antibody responses could
e enhanced by using a combined vaccine regime consisting of
riming with a vaccinia recombinant expressing the HIV enve-
ope and boosting with an envelope protein. Such a trial was
ormally initiated in the US in 1991, priming with HIVAC-1®
nd boosting with VaxSyn®, the two candidate vaccines that had
een already evaluated separately in humans. This prime-boost
pproach had been previously used by Shiu-Lok Hu, then at Bris-
ol Myers/Squibb, to protect macaques against SIV infection [60].
rime-boost regimes were shown to greatly enhance humoral and
ellular immune responses, including the induction of neutralizing
ntibodies [61,62]. Although the ﬁrst vaccinia-prime/protein-boost
rial was conducted by Zagury in 1988 [32], the above described
rime-boost experiments provided ample scientiﬁc evidence that
reatly inﬂuenced the ﬁeld. From the 218 clinical trials conducted
ince 1988, 76 were conducted with different modalities of the
rime-boost approach.
However, the use of the vaccinia virus as a vector had several
ractical concerns. On one hand, the immunogenicity of the vector
s diminished in individuals who have been previously vaccinated
gainst smallpox. But more importantly, the use of replicating
accinia was contraindicated in immunosuppressed individuals,
here its administration could cause severe disease [35,63]. In fact,
 practical HIV vaccine for public health use should be safe in popu-
ations where HIV infection is prevalent. Consequently, attenuated
oxvirus vectors were developed in the early 1990s by Jim Tartaglia
nd Enzo Paoletti, from Virogenetics Corporation (Troy, New York).
hese vectors are based on either a highly attenuated vaccinia virus
NYVAC) or on Canarypox (ALVAC®), an avian poxvirus which does
ot replicate in mammalian cells [54,64]. Another novel poxvirus
ector strategy was the use of the modiﬁed vaccinia Ankara (MVA),
 highly attenuated vaccinia virus originally developed in the mid-
970s which had been given to more than 120,000 people in
ermany in the latest phases of the global smallpox eradication
ampaign. MVA  grows to high titers in chicken embryo ﬁbroblasts,
ut has virtually lost its ability to multiply in mammalian cells
65–67]. Over the last 20 years, 71 trials have been conducted with
ox-virus based HIV vaccines [68].
An ALVAC®-vectored HIV vaccine expressing gp160 (vCP125,
rom Pasteur Merieux/Connaught, Lyon, France) entered clinical
valuation in 1993, and was used alone or in a prime/boost regime
ith an adjuvanted gp160 subunit [69]. The results showed that
he ALVAC® vaccine signiﬁcantly primed the neutralizing antibody
esponse of the protein boost, also inducing CTL activity.
Second generation ALVAC® vectors (vCP205, vCP300, vCP1433,
CP1452, and vCP1521) were constructed to express not only the
IV envelope, but also gag and other HIV genes with the aim
f inducing a broader cell-mediated immune response [70–72].
CP205, which vectored multiple HIV genes (gp120, the anchor
egion of gp41, gag and protease) was the second vaccine tested
n Africa, in Uganda in 1999 [73,74]. Although the vaccine tested in
ganda was based on clade B genes, while the circulating clades
here are A and D, the trial was justiﬁed on the basis of exten-
ive cross-clade cellular responses recently described [75]. And, of
ourse, vCP1521 was the prime used in the Thai RV144 trial [33,71].013) 3502– 3518 3505
5.3. A focus on the V3 loop
Once it was  established that neutralizing antibodies could be
induced by the HIV envelope proteins, the next challenge was  to
identify speciﬁc neutralization epitopes in gp120 that could be used
for vaccine design. This was  achieved by animal immunization with
gp120 segments produced in E. coli [76] and by identifying the
peptides recognized by the neutralizing antibodies in HIV infected
individuals [77]. Much work was  done in this area by the team of
Dani Bolognesi, from Duke University Medical School, and by 1990
there was general agreement in the ﬁeld that the “Principal Neutral-
izing Determinant” (PND) of HIV mapped to the third hypervariable
loop of gp120 (the V3 loop) [78,79]. In fact, Emilio Emini (who was
then at Merck) showed in 1990 that mixing an HIV inoculum with
an anti-V3 monoclonal antibody (mAb) abolished HIV infectivity
for chimpanzees [80].
Immunization of guinea pigs with V3 peptides also induced neu-
tralizing antibodies to HIV [81]. However, it was  fully recognized
at that time that the usefulness of V3 peptides in vaccine design
could be limited by its extensive sequence variability. Another chal-
lenge is that the V3 loop is non-exposed on many primary isolates
of the virus. Many years later, Susan Zolla-Pazner from New York
University, argued that despite the sequence variability there was
a signiﬁcant conservation of the conﬁguration of the V3 loop that
could be exploited for the development of a broadly protective vac-
cine. She felt that the V3 conservation was  related to its central
role in the interaction of the virus envelope with the cell surface
chemokine receptors [82,83].
In the early 1990s, concerns about the sequence variability of
the V3 loop were balanced with the perception that it represented
the principal neutralization determinant of HIV. The expectation
existed that a limited repertoire of synthetic V3 peptides could
meet the requirements for a broadly protective vaccine. With the
leadership of Wayne Koff, who  came from the NIH to work with
United Biomedical Inc (UBI, Hauppauge, NY), the company devel-
oped an octameric synthetic V3 vaccine that entered clinical trials
in 1993 [84]. This product was  the ﬁrst HIV vaccine to be tested in
China, in 1993 [85], as well as in Thailand in 1994 [86]. The vaccine
was  found to be safe and to induce strain speciﬁc neutralizing anti-
bodies [87]. A different V3 loop-based vaccine (TAB9) was tested in
Cuba in 2001[88].
Even though the V3 loop attracted considerable attention as a
potential vaccine target, it was known since the early 1990s that
some infected individuals made broadly neutralizing antibodies
that were targeting conserved conformational epitopes in gp120,
rather than the V3 loop [89]. Those observations reinforced the
concept that conformational epitopes present in native envelope
glycoproteins might protect against a broader range of HIV strains
than a vaccine that presented exclusively linear determinants, such
as those in the V3 loop.
5.4. Animal protection experiments
Different lines of research using NHP provided optimism to the
ﬁeld. In 1990, the groups of Phil Berman at Genentech and Marc
Girard at the Pasteur Institute in Paris, found that immunizations
of chimpanzees with candidate vaccines based on the HIV enve-
lope glycoproteins conferred protection against an HIV challenge
[90,91].
Although chimpanzees are the only NHP that can be readily
infected with HIV, and they were extensively used in HIV vaccine
research, it was  becoming evident that a different animal model
was  needed. Chimpanzees are an endangered species, and their
genetic proximity to humans made it ethically difﬁcult to perform
experiments, especially those involving challenges with virulent
virus [92]. In addition, since chimpanzees were believed not to
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evelop disease after HIV infection, a pathogenic model where the
ffect of vaccination on both acquisition of infection and disease
evelopment, was highly desirable [93].
Consequently, many experimental vaccines were designed
sing SIV as a surrogate for HIV and tested in the macaque model
94]. The expectation was  that such information could then be
xtrapolated to the design of HIV vaccines. The problem, of course,
as that those vaccines were based on the wrong virus (SIV)
nd evaluated in the wrong animal (macaque monkeys). A break-
hrough came around 1990, when teams in the US and Japan
ndependently generated chimeric viruses constructed with the
ag and pol genes of SIV and the env gene of HIV that are capable
f infecting macaques [95,96]. Since then, these chimeric SIV/HIV
iruses, known as SHIV, have been an important although imper-
ect tool, to study in macaques the protective effect of different
mmunogens based on the HIV envelope [97].
Unfortunately, most of the candidate vaccines tested in the SIV-
HIV/macaque models failed to protect against virus acquisition
often referred to as sterilizing immunity). However, many of these
rials resulted in decreased virus load and protection against pro-
ression to disease in vaccinated animals that became infected after
he challenge. Those observations led, as late as in 2007 to the
easonable conclusion that a vaccine capable of achieving steril-
zing immunity might not be a realistic goal and that, perhaps, the
est that could be done was to develop disease-modifying vaccines
98–100]. However, most of the experiments conducted at that
ime used large dose challenges, often administered intravenously,
onditions that were very different from natural infection. Those
arge virus challenges could have overwhelmed any potential
accine-induced protective immune response. To address those
oncerns, a more representative challenge model was  proposed
n 2004, using repeated low-dose challenges of virus administered
ntravaginally [101,102]. This challenge model has now become the
tandard and a number of experimental vaccines have shown to
nduce protection against virus acquisition in the macaque model
103,104].
.5. A faux pas: whole inactivated SIV vaccines
Much excitement was created in 1989 when the groups led by
on Desrosiers from the New England Regional Primate Research
enter, Harvard Medical School, and Mickey Murphy-Corb from the
elta Primate Center at Tulane University, reported that adjuvanted
hole inactivated SIV could protect macaques against a challenge
ith live SIV [105,106]. After all, whole inactivated vaccines have
orked against many other viral diseases. Those ﬁndings were
apidly followed by the report that macaques could also be pro-
ected from SIV by immunization with inactivated preparations
f cells that had been infected with SIV [107]. Suddenly, a criti-
al control was included by Jim Stott and collaborators, from the
ational Institutes for Biological Standards and Control (NIBSC)
n London. To the collective surprise and disappointment, it was
ound that immunization with similar preparations of uninfected
ells also afforded partial protection against SIV [108]. Although it
s known that envelope viruses pick up cellular antigens when bud-
ing from the cell membrane, a fact also established for HIV [109],
ever before have host cell components been shown to be responsi-
le for protection [110]. An analysis of sera from protected monkeys
emonstrated a positive correlation with antibodies to the HLA
lass I molecule [111]. Moreover, experimental immunization with
LA class I antigens protected macaques from SIV challenge, con-
rming that protection was due to xeno-immunization rather than
o a virus speciﬁc immune response [112]. That essentially was the
nd of the road for the use of whole inactivated vaccines aimed
t inducing viral-speciﬁc immune responses in healthy individuals
113].013) 3502– 3518
However, in 1987 Jonas Salk, the developer of the ﬁrst polio
vaccine, proposed the use of inactivated HIV preparations as a ther-
apeutic approach for the immunization of infected patients [114].
This led to the development of Remune®, an inactivated gp120-
depleted immunogen, manufactured by the Immune Response
Corporation (Carlsbad, CA). The company initiated large scale clin-
ical trials in 1996, which were discontinued in 1998 [115].
Nevertheless, the monkey protection experiments described
above stimulated more recent research aimed at inducing protec-
tive immunity using alloantigen-based vaccines, especially by Tom
Lehner, from King’s College London, and collaborators [116–118].
5.6. The live-attenuated vaccine saga
In the early 1990s Ron Desrosiers was studying the in vivo effect
of the SIV accessory genes. In 1992, he reported that deletion of the
nef gene resulted in an attenuated virus that, upon inoculation in
macaques, resulted in protection against a challenge with wild-type
pathogenic strains of SIV [119].
Interestingly, that ﬁnding was consistent with the reports from
the Sydney Blood Bank cohort in which eight accidental recip-
ients of blood containing a nef-deleted strain of HIV were not
progressing to AIDS [120,121]. Those observations opened up the
possibility of considering the development of a live-attenuated HIV
vaccine [122–124]. By that time, the HIV vaccine ﬁeld had suffered
several setbacks and the possibility of a live-attenuated vaccine,
although very risky and controversial, needed to be considered
[125]. The discussion centered around two  possibilities. The use
of live-attenuated HIV strains for human trials or, alternatively, the
use the SIV-macaque model to understand immune correlates of
protection that could inform the development of safer vaccines for
humans. As an act of desperation, or perhaps of altruism, a group of
physicians proposed to volunteer for a trial using a live-attenuated
HIV vaccine in 1997 [126].
The unacceptable risk of using attenuated strains of HIV as a
vaccine was  clearly demonstrated by the team of Ruth Ruprecht,
from the Dana-Farber Cancer Institute at Harvard Medical School,
who  in 1999 reported that multiple deleted SIV mutants could actu-
ally cause AIDS in infant and adult monkeys [127–129]. Moreover,
prolonged observation of the Sydney Blood Bank Cohort, showed
immunological damage in some individuals chronically infected
with the nef-deleted HIV strain [130]. Although those observations
put an end to any consideration of using a live attenuated HIV in
human, the live attenuated SIV model was intensively investigated
by the IAVI Live Attenuate SIV Vaccine Consortium and others [131].
Recent results suggest that protection by live-attenuated virus
might be mediated either by antibody-dependent cell-mediated
cytotoxicity (ADCC) [132] or by persistence of T cells in the lymph
nodes [133], ﬁndings that could inform future HIV vaccine devel-
opment.
5.7. Preparing for international vaccine trials
Partially driven by the above monkey protection experiments,
a sense of urgency developed in the early 1990s to prepare
international sites to conduct efﬁcacy trials of the HIV vaccines,
which some expected to be available in the forthcoming years. In
1990, WHO  formed its HIV Vaccine Advisory Committee, initially
chaired by Hans Wigzell, from the Karolinska Institute. That same
year, WHO  began the process of identifying potential vaccine
evaluation sites and initiated discussions with Brazil, Rwanda,
Thailand and Brazil. These discussions led to the development of
“National AIDS Vaccine Plans” [134,135]. An important component
of site preparation was the development of ethical guidance for the
conduct of HIV vaccine trials [136]. With the exception of Rwanda,
where a genocidal war  started in 1994, the three other countries
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ecame pioneers in the international testing of HIV vaccines
39,40,73,74,137–140].
The major HIV vaccine player over the years has undoubtedly
een the US National Institutes of Health (NIH). NIH established its
ivision of AIDS (DAIDS) in 1986 and the Ofﬁce for AIDS Research
OAR) in 1988. The AIDS Vaccine Evaluation Group (AVEG), cre-
ted in 1988, conducted most of the early phase I trials of HIV
accines. The HIV Network for Prevention Trials (HIVNET) was
ormed in 1993 to conduct domestic and international multi-center
rials to evaluate the safety and efﬁcacy of promising HIV pre-
entive interventions including, but not limited, to vaccines. To
repare for international vaccine trials, in 1993 the NIH launched
he “Preparation for AIDS/HIV Vaccine Evaluation” (PAVE) projects,
ith international sites in Haiti, India, Kenya, Malawi, Rwanda,
hailand, Uganda, and Zimbabwe [141].
A 1993 review of the NIH AIDS activities led to some important
hanges, including the 1994 reorganization of the OAR [142], the
ublication of the inﬂuential Levine Report in 1996 [143] and the
stablishment (the same year) of the AIDS Vaccine Research Com-
ittee led by David Baltimore [144]. In 1999 the HIV Vaccine Trials
etwork (HVTN) was established under the leadership of Larry
orey to conduct all phases of clinical trials. The HVTN, which is
eadquartered at the Fred Hutchinson Cancer Research Center in
eattle, WA,  currently conducts the large majority of the HIV vac-
ine trials through an international network of Vaccine Trial Units
145].
Other international HIV vaccine programs established in the
980s included the Directed AIDS Research Programme of AIDS
esearch of the UK Medical Research Council, launched in 1987
nder the leadership of Geoffrey Schild [146], and the French
ational Agency for AIDS Research (ANRS) that, who in 1992 initi-
ted clinical trials of recombinant canarypox viruses (ALVAC) [147]
nd later of lipopetide immunogens [148]. From 1986 ANRS and
asteur Merieux convened in France the “Cent Gardes” Colloquia,
here every year the latest HIV vaccine science was  discussed.
talian investigators explored the potential vaccine use of Tat, a
egulatory HIV protein [149], and Russia established more recently
ts own HIV vaccine development program [150].
The South African AIDS Vaccine Initiative (SAAVI) was estab-
ished in 1999 under the leadership of Malegapuru William
akgoba, to coordinate and support the development and test-
ng of HIV vaccines in South Africa. SAAVI focused on vaccines
ased around clade C strains, which are the most prevalent in
outhern Africa [151]. With the support from WHO, in 2000 the
African AIDS Vaccine Programme” (AAVP, now “Partnership”) was
aunched, with the goal of mobilizing support and advocating for
 more Africa-focused HIV vaccine agenda [152]. More recently,
 similar regional initiative has been launched for Asia (the AIDS
accine for Asia Network—AVAN) [153].
.8. The emerging picture of HIV clades
Genomic sequencing of HIV isolates from many parts of the
orld began to reveal genotypic differences among different
solates, which were initially classiﬁed either as African or North-
merican strains. By 1991 it was clear from sequencing data of the
nv gene that there were at least ﬁve distinct lineages of the virus,
sually referred to as genetic subtypes or clades. For the sake of sim-
licity, they were designated by the late Gerald Myers and Better
orber, from the Los Alamos National Laboratory, as A, B, C, D, and
 subtypes [154]. Most of these subtypes were also subsequently
stablished based on sequence of the gag gene [155].In 1992, led by Saladin Osmanov, WHO  formally established
 network for HIV isolation and characterization. The network
onitored HIV variability on a global basis, with a special focus on
he four initially selected vaccine evaluation sites [156,157]. WHO013) 3502– 3518 3507
subsequently reported that by 2000 the largest incidence of HIV-1
infections was due to subtype C strains (47.2%), concentrated in
southern Africa [158,159].
A pressing question at that time was if the HIV clades corre-
lated with immunological subtypes or immunotypes. Initial data,
comparing isolates from the US and Thailand, indicated that they
belonged to two  different immunotypes that correlated with viral
clades B and E, respectively [160]. Those immunotypic differences
suggested that a broadly effective vaccine may have to include
strains from multiple clades (until that time all candidate vaccines
were based on clade B strains). When more complex virus/antibody
matrices were studied, the conclusion was that potential neu-
tralization serotypes (or immunotypes) do not directly correlate
with the genotype [161,162]. The potential existence of HIV
immunotypes is currently been investigated using a comprehen-
sive neutralization checkerboard using approximately 200 viruses
and 200 plasma samples from chronically infected individuals
(Monteﬁori DC, personal communication).
5.9. The virus neutralization surprise
As discussed before, many of the enveloped-based candidate
vaccines tested in the 1980s and early 1990s were found to induce
neutralizing antibodies in animal models and human trials. How-
ever, in 1994 it was  found that those vaccine-induced antibodies
were capable of neutralizing laboratory adapted strains of HIV, even
though they could not neutralize isolates obtained from patients,
usually referred to as primary, clinical or ﬁeld isolates [163–167].
That observation had important implications for vaccine develop-
ment since it was felt that a protective immune response should be
effective against the clinically relevant transmitted virus.
To understand the above observation, we need to go back to
1988 when investigators in Sweden, led by Eva-Maria Fenyö and
Birgitta Asjö, described biological differences among HIV strains
that were classiﬁed as either slow/low or rapid/high according
to their capacity to replicate in vitro [168,169]. That classiﬁca-
tion broadly corresponded with another classiﬁcation proposed
the same year by Dutch scientists. It was based on the abil-
ity to induce syncytium in activated peripheral mononuclear
cells (PBMC), deﬁning non-syncytium inducing (NSI) or syncytium
inducing (SI) strains [170]. An additional viral phenotype was
deﬁned by the in vitro cell tropism, either as T-cell or macrophage
tropic viruses, which also showed some correlation with the two
other biological phenotypes discussed before [171,172]. Moreover,
those biological features were found to correspond to the severity
of HIV infection [173]. Progression to disease was associated with a
shift from monocytotropic to T-cell-tropic virus population [174].
Of relevance to vaccine development, it was also found that virus
strains transmitted between individuals are usually macrophage or
dual tropic (being also slow/low and NSI) and cannot replicate in
transformed T-cell lines [175].
The explanation for the biological phenotypes described in the
previous paragraph was found in 1995/1996, with “the unexpected
encounter of HIV and the chemokine system” [176–179]. Although
it has been known since 1984 that the CD4 molecule is the main
receptor for the virus [180,181], it was  also known that the pres-
ence of CD4 in the cell surface was  not sufﬁcient for HIV infection.
The missing factors were the co-receptors that HIV uses to infect
the target cells, either CCR5 or CXCR4 or both. With that new under-
standing, HIV strains using the CCR5 co-receptor are classiﬁed as
R5, and are usually macrophage-tropic and non-syncytia-inducing.
On the other hand, viruses using the CXCR4 co-receptor are known
as X4, and are usually T-tropic and syncytia-inducing [182].
However, the attractive possibility that the in vitro sensitivity of
HIV isolates to neutralization was  due to different co-receptor use
(with X4 strains being more susceptible), which was found to be
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ntrue and most likely dependent on factors other than co-receptor
sage [183–185].
In any case, the ﬁeld reached the conclusion that vaccine-
nduced neutralizing antibodies should be able to neutralize a wide
ange of strains likely to be encountered in the real world, and
ot just a limited set of highly sensitive X4 laboratory strains. To
acilitate the identiﬁcation of vaccines with enhanced capacity for
liciting cross-neutralizing antibodies, a tiered system was pro-
osed in which the overall potency and breadth of the responses
s assessed with a panel of well characterized viruses with differ-
nt sensitivities [186,187]. The question remains of what is the
elevance of the current in vitro neutralization assays regarding
otential vaccine protection in humans, and alternative neutral-
zation assays are being currently explored [188,189]. Ultimately,
he predictive value of any of these in vitro assays would only be
nown when correlates of protective immunity are identiﬁed in
fﬁcacy trials.
Answers to this “neutralizing antibody problem” [190] may
ome from a better understanding of the molecular structure of the
IV envelope protein. A ﬁrst step in that direction was  taken in 1998
y Peter Kwong, then at Columbia University and now at the NIH
accine Research Center (VRC), when he published the ﬁrst crystal
tructure of gp120 [191,192]. Interestingly, despite dramatic bio-
ogical differences between primary and laboratory-adapted HIV
trains, their envelope core structure was found to be quite similar.
his suggested that neutralization resistance is speciﬁed by qua-
ernary interactions involving the variable loops [193]. More recent
ata from the laboratory of Joe Sodroski, at Harvard Medical School,
ndicates that HIV entry into cells as well as sensitivity to anti-
odies may  depend on the “intrinsic reactivity” of the virus, which
s deﬁned as the ability of the envelope glycoproteins to negoti-
te transitions to lower stages of energy after stimulation [194].
he recent description of the subunit organization of the envelope
rimer of HIV, by the Sodroski team, may  provide additional clues
o help designing the appropriate immunogens [195].
Current efforts to develop envelope based vaccines focus on
he use of primary viruses isolated the weeks following clinical
nfection (referred to as transmitted/founder viruses). They have
een shown to have biological properties that could be relevant for
nduction of protective immunity [196].
.10. New energy in the ﬁeld
The accumulation of new scientiﬁc knowledge during the 1990s
ed to renewed energy in the ﬁeld, exempliﬁed by three main
vents: the “Clinton challenge”, the launching of the AIDS Vaccine
dvocacy Coalition (AVAC), and the establishment of IAVI.
On May  18, 1997, during a commencement speech at Morgan
tate University in Baltimore, US President Bill Clinton challenged
he scientiﬁc community to develop an HIV vaccine within 10 years.
e made of this challenge a national goal for science, comparing it
o President Kennedy’s challenge 36 years earlier, to land a man
n the moon before the end of the 1960s [197,198]. Since then,
ay  18 has become “HIV Vaccine Awareness Day”. To achieve the
oal, President Clinton recommended a signiﬁcant increase in the
overnment budget for HIV vaccine research and announced the
reation of the NIH Vaccine Research Center (VRC), with Gary Nabel
ppointed as its ﬁrst Director [199]. Most scientists were against
romising a vaccine within a speciﬁc period of time, but some
rgued that having such a goal would energize the ﬁeld and convey
he necessary sense of purpose and urgency. Although no promises
ere made, it is interesting to note that the ﬁrst efﬁcacy signal of
n HIV vaccine (the RV144 trial) came 12 years later, in 2009, not
oo far from the 10 years challenge.
AVAC was founded in 1995, in large part due to the efforts
f Bill Snow, a long time HIV vaccine advocate, to accelerate the013) 3502– 3518
development of an HIV vaccine through education, policy analysis
and advocacy. In 1998 AVAC published its ﬁrst annual report,
entitled “9 Years and Counting” alluding to President Clinton’s
commitment to develop an HIV vaccine in 10 years [200]. In 2009,
under the leadership of Mitchell Warren, AVAC broadened its
mandate to become the “Global Advocacy for HIV Prevention”.
In 1996 IAVI was established under the leadership of Seth
Berkley, based on a recommendation made by a group of experts
convened by the Rockefeller Foundation in 1994 in Bellagio, Italy.
In 1997, IAVI launched a “Call for Action” and in 1998 issued its ﬁrst
Scientiﬁc Blueprint for AIDS Vaccine Development. In 2011, Margie
McGlynn, a former head of Merck’s vaccines and infectious dis-
eases, became the second IAVI director after Seth Berkley assumed
the leadership of the GAVI Alliance.
5.11. The ﬁrst two efﬁcacy trials: VaxGen
By 1994, two gp120 products emerged as potential candidates
for an efﬁcacy trial. Genentech and Chiron/Biocene have spent eight
years testing envelope based vaccines in animal models and phase
I/II clinical trials in humans. These vaccines had been shown to be
safe and immunogenic in phase I clinical trials and to protect chim-
panzees from an HIV challenge [90,201]. On the other hand, the
recent ﬁnding that the antibodies induced by those vaccines failed
to neutralize primary isolates of HIV threw a cloud of doubt over the
scientiﬁc rational for advancing their clinical evaluation. Moreover,
the chimpanzee protection experiments were done with laboratory
adapted strains of the virus and their relevance for human protec-
tion was  not clear. In view of the urgency imposed by the epidemic,
especially in developing countries, the dilemma that the scientiﬁc
community confronted was  between adopting a cautious strategy
of more basic research versus a more aggressive approach based
on “thoughtful empiricism” [202]. That dilemma was discussed in
1994 by two  advisory groups of the NIAID: the HIV Vaccine Work-
ing Group and the AIDS Research Advisory Committee (ARAC). After
considering the possibility of moving ahead with a scaled down
efﬁcacy trial, the NIAID ﬁnally decided not to support the proposed
efﬁcacy evaluation of the candidate vaccines [203].
The NIAID decision stimulated a broader discussion that led
WHO to make in 1994 a recommendation encouraging efﬁcacy test-
ing of HIV vaccines in developing countries where the epidemic is
most severe [204–207]. In addition, the negative decision of the
NIAID did not discourage Don Francis, who  had earlier moved from
the CDC to Genentech, who decided to leave Genentech and start a
new company, VaxGen (South San Francisco, CA). VaxGen sole pur-
pose was conducting efﬁcacy evaluation of the Genentech gp120
vaccines [208]. It took four additional years of preparations and
discussions before VaxGen started its ﬁrst efﬁcacy trial in North
America (VAX004) and Thailand (VAX003) [209–212]. Taking into
account the recently gained knowledge about the genetic variabil-
ity of HIV strains and the use of different co-receptors, the original
candidate vaccines were redesigned as bivalent gp120 preparations
(AIDSVAX® B/B or the North American trial and AIDSVAX® B/E for
the Thai trial) derived from R5 and X4 strains [213]. The two efﬁcacy
trials were done from 1998 to 2003, involving 5417 volunteers in
VAX004, (mostly men-who-have sex-with-men in North America)
and 2545 volunteers in VAX003 (injecting drug users in Bangkok,
Thailand) (Fig. 2).
The ﬁnal results of these two trials were reported in 2003, indi-
cating that the vaccines failed to confer protection against HIV
[41,42]. A post hoc analysis suggested that in the North Ameri-
can trial (VAX004) women  and African-Americans may  have been
somehow protected. This claim caused considerable confusion and
controversy [214–217]. Many scientists who had expressed dis-
agreement with the conduct of these trials, felt vindicated by
the negative results. The claims of potential efﬁcacy in some
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opulations triggered a negative reaction from the scientiﬁc com-
unity that, in part, prevented or delayed a thorough scientiﬁc
nalysis of the data and samples obtained from these trials. For-
unately, samples from VAX003 and VAX004 were stored and
ecently analyzed. They were compared with results from the
V144, revealing important information that may  be related to
rotection [218,219].
After these two trials, Don Francis, Phil Berman and other key
layers in the gp120 efﬁcacy trials left VaxGen in 2004 to start
lobal Solutions for Infectious Diseases (GSID), a non-proﬁt organi-
ation engaged in the development of vaccines and other products.
hrough the provision of AIDSVAX B/E, GSID was  a partner in the
V144 trial.
. Second wave of HIV vaccine trials: induction of CTL
esponses (1995–2007)
A second wave of HIV vaccine trials began with the recogni-
ion in the early 2000s of the critical importance of CD8+ T-cell
esponses in the control of HIV infection, especially due to the
ork of Bruce Walker from the Massachusetts General Hospital and
ndrew McMichael from the University of Oxford [220–223]. This
aradigm led to the development and reﬁnement of live recombi-
ant viral vectors, especially pox and adenovirus vectors, as well
s DNA vaccines [224,225,68]. We  suggest that this period was  for-
ally concluded in 2007 with the unexpected lack of efﬁcacy in
he STEP trial, which evaluated a cell-mediated immunity vaccine
ased on an adenovirus type 5 (Ad5) vector expressing HIV-1 gag,
ol and nef [226].
.1. Re-examining the global strategy
The negative results from the VaxGen gp120 trials catalyzed
 rethinking in the ﬁeld with a re-examination of the scientiﬁc
asis for the development of an HIV vaccine, as well as the search
f mechanisms for a more strategic and coordinated approach to
olve the HIV vaccine challenge. In 2003, an international group of
cientists proposed the creation of a global HIV Vaccine Enterprise
s a new collaborative model of research to accelerate the global
ffort to develop an HIV vaccine [227]. Two years later, the Enter-
rise published its ﬁrst Scientiﬁc Strategic Plan [228] identifying
cientiﬁc priorities and making recommendations to address
hem. The Bill & Melinda Gates Foundation served as the interim
ecretariat of the Enterprise until early in 2008 when a permanent
ecretariat was established in New York under the leadership off HIV vaccines.
Alan Bernstein. The Enterprise secretariat continues functioning in
New York, currently under the direction of Bill Snow [229–234].
Perhaps the two most direct responses to the Enterprise vision
was  the creation of the NIH-funded Center of HIV Vaccine Immunol-
ogy (CHAVI) in 2005, directed by Barton Haynes from Duke
University [235,236], and the 2006 launching of the Bill & Melinda
Gates Foundation supported Collaboration for AIDS Vaccine Dis-
covery (CAVD) [237]. Both programs are still in existence. The
Enterprise also inspired the creation of Europrise, a Network of
Excellence supported by the European Commission which oper-
ated between 2007 and 2012 [238], as well as the establishment of
the Canadian HIV Vaccine Initiative (CHVI).
6.2. Lessons from natural history
It has been known since the early 1990s that infected peo-
ple mount vigorous CTL responses to HIV [239,240] and these
responses were considered as potential effectors of future HIV vac-
cines [223,241,242]. The 2000 decade saw much work trying to
understand the dynamic of cellular immune responses in natural
infection and in animal models [243–246]. Those studies provided
strong evidence that CTLs were important in controlling virus repli-
cation in infected people, although not sufﬁcient to completely
eliminate the virus or suppress it indeﬁnitely [247].
The “pessimistic expectation that the gp120 vaccine would not
offer signiﬁcant protection against primary HIV infection” was a
powerful incentive to turn the attention to the cell mediate arm
of the immune system, in particular to vaccines that can stimulate
CD8+ T cells [248]. That was pursued mostly through the develop-
ment of DNA immunization and the use of viral vectors.
6.3. The excitement of DNA vaccines
Several research groups reported some 20 years ago, in the
early 1990s, that plasmid DNA delivered into the skin or muscle
induced viral speciﬁc antibody responses [249–252]. This relatively
simple technology was  seen as a potential modern replacement
of live-attenuated vaccines, capable of inducing a whole range
of immune responses [253]. In the mid-1990s the potential of
DNA vaccination was explored in the SIV/macaque model by
different teams, especially those lead by David Weiner (from the
University of Pennsylvania School of Medicine), Harriet Robinson
(then at Emory University), and Shan Lu (from the University
of Massachusetts Medical School). Those studies indicated that
vaccination elicited persisting SIV-speciﬁc CTL although protection
3 e 31 (2
a
a
l
t
a
v
b
b
e
e
r
t
h
d
b
s
o
o
o
p
[
t
I
w
c
d
C
l
(
i
t
i
6
o
v
t
t
v
t
d
o
g
t
s
[
a
a
[
t
d
u
i
g
T
d
o510 J. Esparza / Vaccin
gainst SIV challenges was  not readily demonstrated in vaccinated
nimals only showing reductions in virus load [254–259].
However, it was rapidly found that the robust immunogenicity
evels obtained with DNA immunization in small animals did not
ranslate to NHP and to humans. To address that problem, different
pproaches were explored to enhance the immunogenicity of DNA
accines, including: the use of routes of administration that com-
ined priming with particles coated with DNA (gene-gun) followed
y intramuscular and intradermal inoculation [260,261]; in vivo
lectroporation [262–265]; co-administration of DNA and differ-
nt cytokines [266–269]; and boosting with different vectors or
ecombinant proteins [270–273].
Although at least four DNA vaccines have been approved in
he area of veterinary medicine, none have yet been licensed for
uman use [274]. Nevertheless, according to the IAVI clinical trials
atabase [36], 10 phase I clinical trials of HIV DNA vaccines have
een conducted since 2001 [275,276]. Those early human trials
howed disappointing levels of immune responses casting a doubt
n the utility of DNA vaccines for human application [277].
Two studies published in 2008 provided evidence on the utility
f DNA priming after boosting with either a vaccinia vector [278]
r recombinant gp120 proteins [279]. Different approaches of DNA
riming and heterologous boosting continue to be explored to date
280–284].
In fact, the latest efﬁcacy trial of an HIV vaccine, HVTN 505,
ested a DNA-primed candidate vaccine developed by the NIH VRC.
t consisted of a prime-boost regimen involving three vaccinations
ith DNA encoding HIV clade B gag, pol,  and nef,  and env from HIV
lades A, B, and C, followed by an Ad5 vector-based vaccine can-
idate encoding clade B gag and pol,  and env from clades A, B, and
 [285–287]. The trial, which was sponsored by the US NIH, was
aunched in 2009 with the ﬁnal results originally expected by 2015
Fig. 2). Unfortunately, the trial was stopped in April 2013, after an
nterim analysis revealed that the vaccine failed to prevent infec-
ion or to reduce virus load in vaccinated volunteers who became
nfected.
.4. The rise of viral vectored vaccines: poxvirus and adenoviruses
Two viral vectors have been preferentially used for the devel-
pment of HIV vaccines, poxviruses and adenoviruses.
Although poxvirus vectors were the ﬁrst to be used for HIV
accines, the emphasis during this wave shifted to adenovirus vec-
ors. Work continued on the poxvirus front, mostly because of
he work of three laboratories exploring different strains of the
accinia virus: Gepi Pantaleo in Lausanne exploring novel vec-
ors based on NYVAC, a highly attenuated vaccinia virus strain
erived from the Copenhagen vaccine strain from which 18
pen reading frames had been selectively deleted from the viral
enome [68,288]; Tom Hanke in Oxford, working with MVA  vec-
ors [67,289]; and Yiming Shao in Beijing using the Tian Tan
train, used in China during the smallpox eradication campaign
290]. Genetic manipulation of the vectors and HIV gene inserts
re being used to develop vaccinia vectors with improved innate
nd adaptive immunogenicity, especially when primed with DNA
278,291–293].
But, as mentioned before, the main paradigm explored during
his phase was the use of adenovirus vectors, which were originally
eveloped for the treatment of genetic disease and subsequently
sed as vaccine vectors [225,294]. Adenovirus vectors have been
ntensively explored as a vector for HIV vaccines, mostly with the
oal of eliciting HIV-speciﬁc cellular immune responses [294–297].
he IAVI clinical trials database [36] lists a total of 42 clinical trials of
ifferent adenovirus vectors conducted since 2003, by themselves
r in prime-boost combinations.013) 3502– 3518
A major driving force of the adenovirus vector effort was  the
pharmaceutical company Merck & Co, Inc. (Whitehouse Station,
NJ) which in 2001 publically announced results from their initial
NHP protection experiments [298,299]. Their attention was focused
on the use of a replication-defective adenovirus 5 (Ad5) vectors
expressing the SIV gag gene, which in macaques was able to induce
attenuation of viral infection after challenge [300]. Based on these
results a candidate vaccine using a mixture of recombinant Ad5
vectors expressing the HIV gag, pol and nef genes from subtype B
(known as MRKAd5® HIV-1gag/pol/nef was tested in phase I clini-
cal trials and found to be safe and immunogenic [301]. This was the
vaccine used in the STEP and Phambili trials (see below).
An early concern related to the potential use of the Ad5 vec-
tor was  that preexisting immunity to adenovirus 5, which is
prevalent in human populations, especially in less developed coun-
tries [302], could impair the immunogenicity of the Ad5 vector.
Although initial evidence from phase I clinical trials indicated that
the MRKAd5® HIV-1gag/pol/nef was in fact capable of eliciting
immune responses in participants who  were both Ad5 seroneg-
ative and Ad5 seropositive, the ﬁeld began to explore the use
of other alternatives. Under the leadership of Dan Barouch from
the Beth Israel Deaconess Medical Center in Boston and others,
efforts are currently underway to develop novel vectors based on
less prevalent human adenovirus types, or on simian adenoviruses
for which no preexisting immunity exists in human populations
[225,294,303–306]. In this regard it is important to emphasize that
adenovirus vectors are complex biological entities and not simple
physical carriers of foreign vaccine inserts. Different adenovirus
serotypes have different biological properties that might inﬂuence
their safety, immunogenicity and potential efﬁcacy as vaccine vec-
tors.
6.5. The STEP trial
The potential efﬁcacy of the MRKAd5® HIV-1gag/pol/nef vac-
cine was  tested in the STEP trial, with the co-sponsorship of the
NIH/NIAID and Merck. Enrolling began in December 2004 where
they ultimately recruited 3000 participants in Australia, Brazil,
Canada, the Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico
and the United States. In all these countries HIV subtype B is preva-
lent (the same subtype as in the vaccine). The goal of this phase
IIb “test-of-concept” study was to determine if the vaccine could
prevent HIV infection, reduce the amount of HIV in those who do
become infected, or both. In 2007 the same vaccine also entered
phase IIb evaluation in South Africa (the Phambili trial), to explore
if it would also be effective at preventing infection from HIV sub-
type C, which is prevalent in southern Africa. That was a testable
possibility in view of the cross-clade reactivity of CMI  responses
against HIV.
However, in September 2007 both studies (STEP and Phambili)
were halted because an interim review of the STEP trial revealed
that the vaccine was not effective [307]. In a multivariate analysis
of baseline risk factors, vaccination appeared associated with an
increased risk of HIV acquisition in certain volunteers. When the
ﬁnal results of the trial were formally published in November 2008,
the authors concluded that the type of cell-mediated immunity
induced by this vaccine did not prevent HIV infection or reduce
early viral load [226]. A post hoc analyses of the STEP trial con-
ﬁrmed that more HIV infections occurred in vaccinees vs. placebo
recipients in men  who had Ad5-neutralizing antibodies and/or
were uncircumcised, although the vaccine-associated risk waned
with time from vaccination [308].The negative results from this trial came as a surprise to the
scientiﬁc community who  had high expectations with this CMI
approach [309–314]. After these disappointing results, the NIAID
held a scientiﬁc summit in March 2008 with the call to return
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o basic science [315]. The meeting recommended broadening the
esearch agenda to answer fundamental questions in HIV vaccine
iscovery through laboratory, nonhuman primate (NHP), and clini-
al research carefully prioritizing the effort to energize HIV vaccine
iscovery [316].
. Third wave of HIV vaccine trials: combinations of
ifferent immune responses (from 2007)
We  propose that the third and current wave of HIV vaccine
esearch was initiated after the announcement of the disappoint-
ng results from the STEP trial. The scientiﬁc community realized,
nce again, that the development of an HIV vaccine is one of the
ost difﬁcult challenges that biomedical science is confronting.
his wave, that hopefully will take us to the development of an
ffective vaccine, should learn from past failures and systemati-
ally explore different alternatives, including novel concepts that
o not fell within any of the current paradigms.
.1. The RV144 surprise
The negative results from the STEP trial, announced in
eptember 2007, were contrasted with the surprisingly posi-
ive (although modest) results of the RV144 trial announced two
ears later, in October 2009. RV144 tested a prime-boost recom-
inant vaccine against HIV among 16,402 adults in Thailand,
rom September 2003 to August 2009 (Fig. 2). The trial was  an
xtraordinary collaboration of Thai scientists (particularly Supachai
erks-Ngarm and Punnee Pitisuttithum) and US investigators (Nel-
on Michael and Jerome Kim, from the Military HIV Research
rogram), with support from the NIH and participation from Sanoﬁ
nd GSID. The trial tested the protective efﬁcacy of a “prime-boost”
ombination of two vaccines: ALVAC® (the vCP1521 canarypox vec-
or manufactured by Sanoﬁ Pasteur) and AIDSVAX® B/E vaccine
the Genentech gp120 proteins previously tested in VAX003 and
AXX04, supplied by GSID) (see Section 5.11).
The trial demonstrated a 31.2% efﬁcacy in preventing HIV infec-
ion [33]. Although the initiation of this trial was marred by
ontroversy [317,318], and the initial results were received with
onsiderable skepticism [319], the ﬁeld ultimately accepted the
esults. They were most especially accepted after the publication
n May  2012 of an immune correlates analysis coordinated by
art Haynes from Duke University [320]. This immune-correlates
tudy generated the hypotheses that V1V2 antibodies may  have
ontributed to protection against HIV-1 infection, whereas high
evels of Env-speciﬁc IgA antibodies may  have mitigated the effects
f protective antibodies. This analysis failed to identify neutral-
zing antibodies as a potential correlate, turning the attention to
 potential role of non-neutralizing antibodies, probably to those
nvolved in mediating antibody-dependent cell-mediated cytotox-
city (ADCC) [132,321].
The immune correlate information, as well as information sug-
esting that vaccine efﬁcacy in RV144 appeared to wane from 60%
t 12 months to 31.2% at 3.5 years [322,323] is being considered in
he design of candidate vaccines and clinical trials aiming to build
n the modest efﬁcacy achieved in the RV144 trial [324]. Discuss-
ons are under way to conﬁrm and extend results from RV144 in
ther populations, including southern Africa (Fig. 2).
To some extent, the modest success obtained with the RV144
rial brought new attention to the importance of conducting clini-
al trials, especially efﬁcacy trials, to complement the basic research
ffort [14]. As mentioned before, the RV144 trial also provided
nformation suggesting that antibodies were important in confer-
ing protection against acquisition of HIV infection. This, taken
ogether with the failure of the CMI  vaccine tested in the STEP trial,013) 3502– 3518 3511
turned the HIV vaccine paradigm pendulum back to the induction
of antibodies. This ultimately may  be needed to confer steriliz-
ing protection in vaccinated individuals, or at least to prevent the
establishment of chronic infection [325].
7.2. Broadly neutralizing antibodies and structure-based
immunogen design
The Holy Grail of HIV vaccine research has been the devel-
opment of immunogens capable of eliciting broadly neutralizing
antibodies that can protect against the large number of immuno-
logical different strains that circulate globally [231], an approach
that has been championed for many years by the IAVI Neutraliz-
ing Antibody Consortium under the leadership of Dennis Burton,
from the Scripps Research Institute in La Jolla, and IAVI’s Wayne
Koff [190].
A major frustration in the ﬁeld is that after many years of
research with different versions of the HIV envelope glycoproteins,
these products have failed to induce antibodies capable of neutral-
izing primary isolates of the virus. Nevertheless, it is known that
some humans infected with HIV do develop antibodies that are
capable of neutralizing different strains of the virus (broadly neu-
tralizing antibodies), providing a hope that one day we  would be
able to induce those antibodies with a vaccine [326,327]. In fact, as
early as 1992, broadly neutralizing monoclonal antibodies (bnmAb)
targeting different HIV epitopes have been isolated and character-
ized [328–332], and in recent years there has been an explosion of
new bnmAb against HIV, especially because of the work at Scripps,
the VRC, the CAVD team of Robin Weiss and Antonio Lanzavec-
chia, and more recently, the laboratory of Michel Nussenzweig at
The Rockefeller University [333–338]. The epitopes recognized by
those bnmAbs are being explored as potential immunogens for vac-
cine development by different laboratories, particularly at Scripps
and the VRC [190,339,340].
This structure-assisted approach to immunogen design has
beneﬁted from recent information on the molecular structure of
the HIV envelope glycoprotein and the critical epitopes that are
targeted by bnmAbs [341–344]. We  have learned much of the
unique characteristics of these bnmAbs, including polyreactiv-
ity for host antigens, extensive somatic hypermutation and long,
variable heavy-chain third complementarity-determining regions
[345]. However, a major challenge that the ﬁeld is confronting is
the dissociation between antigenicity (the ability of a molecule to
be recognized by given monoclonal antibodies) and immunogenic-
ity (the ability of those molecules to induce in animals or humans
the corresponding antibodies). That challenge is being addressed
by efforts that combine expertise in structural biology (to design
the right type of immunogen) with B-cell biology (to ensure that
the host immune response recognize the immunogen and drive the
production of antibodies of the desire quality) [345,346].
8. Concluding comments
Three decades of HIV vaccine research has taken the ﬁeld
through a roller coaster of many failures and a few modest suc-
cesses. In occasions, especially after results from failed efﬁcacy
trials are announced, there have been calls to give up the devel-
opment of an HIV vaccine [309,347]. Those suggestions have been
followed by well-argued rebuttals [325,348].
However, it is fair to say that results from efﬁcacy trials have
also been instrumental in changing the prevailing paradigms in HIV
vaccine research. Every time results from efﬁcacy trials of HIV can-
didate vaccines are announced, surprising information is obtained
that in many cases, have forced the ﬁeld to change the prevalent sci-
entiﬁc paradigm [14]. The negative results from the gp120 VaxGen
trials in 2003 [41,42] shifted the main efforts from vaccines aimed
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t inducing neutralizing antibodies to vaccines that induce CTLs.
ikewise, the failure of the STEP trials in 2007 [307,226] stimulated
 re-examination of the scientiﬁc strategy for the development of
n HIV vaccine, shifting the emphasis to basic research [315,316].
hen we were still assimilating the lessons from the STEP trial, we
earned in 2009 of the modest success of RV144 in Thailand [33].
his stimulated a new interest in addressing HIV vaccine develop-
ent, not only through basic research, but also with well-planned
linical trials. The recent failure of HVTN 505 will undoubtedly
rigger another round of soul searching.
It has been shown once and again that basic research has unde-
iable value, but that it alone will not produce a vaccine. The
ptimum balance between discovery and development is not easy
o strike, but exclusive focus on either extreme of this spectrum is
nlikely to represent the best strategy [13,14]. Human data trump
verything we do in vitro or in animal models, and we need to be
repared to expect the unexpected and rapidly build on the results
14].
The current effort to rationally design an HIV vaccine needs to
e pursued, although there are voices that warn that a strict reduc-
ionist approach may  actually hamper the effort. Rational vaccine
esign efforts need to be complemented with strategically planned
mpirical immunogenicity and efﬁcacy evaluations [349,350]. Dur-
ng this current third wage of HIV vaccine development, vaccines
esigned to engage both arms of the immune system, humoral
nd cellular, need to be pursued more strategically [351]. This is
articularly important because evidence is increasingly showing
hat a humoral immune response to vaccines may  be required
o prevent acquisition of infection, while CTL may  be the criti-
al response in controlling virus replication in vaccinated subjects
ho become subsequently infected [352,353]. The results from the
V144 trial also brought new attention to the potential role of
ucosal immunity, a topic that deserves much more attention in
he future [232,354–357].
It is essential to explore innovative approaches and welcome,
ot dismiss, innovative approaches that may  not conform to cur-
ent scientiﬁc orthodoxy [14]. A case on point is the potential role
f non-neutralizing antibodies that may  confer protection through
ther mechanisms [321,358,359]. Another area for future explo-
ation, although controversial, is the potential non-cytolytic effects
f CD8+ cells [360–364]. To accelerate the clinical development
f some of these new concepts, small and intensive experimen-
al medicine trials, to rapidly obtain safety and immunogenicity
ata, need to be seriously considered as a complement to the
ost traditional progression though clinical trial phases used today
365].
It is concerning that after many years of intense research,
he identiﬁed scientiﬁc challenges confronting HIV vaccine devel-
pment have not qualitatively changed [5,7,11,366]. They were
and continue to be) related to the lack of natural protective
mmune responses in HIV infected persons that could be repro-
uced with a vaccine; the lack of information on immune correlates
f protection; the limitation of primate experiments in predict-
ng vaccine-induced protection in humans; and the signiﬁcance
f genetic and immunological variability of HIV strains in relation
o potential vaccine efﬁcacy. However, recent research is provid-
ng critical new insights on the evolutionary race between virus
volution and the protective antibody response elicited in infected
ndividuals [367,368]. Novel vaccine design, with immunogens that
arget speciﬁc germline B cell receptors, might ﬁnally achieve the
ong-sought goal of inducing broadly neutralizing antibodies [369].
After roughly 30 years of HIV vaccine research, only ﬁve efﬁcacy
rials have been conducted [37,38] (Fig. 2) and only one (RV144)
rovided evidence of protective immunity, although it was  at a very
odest level. The ﬁeld needs to learn, assimilate and accept lessons
rom history [14]. Perhaps the disappointment caused by the recent013) 3502– 3518
failure of HVTN 505 will catalyze, again, a re-examination of the
global HIV vaccine strategy just as it happened in 2003 after the fail-
ure of the VaxGen gp120 trials. This led to the establishment of the
Global HIV Vaccine Enterprise, which now needs to be revitalized.
Today, more than ever, we  need a well-coordinated global effort
with an open mind to re-examine the scientiﬁc challenges and
opportunities. We  must be ready to explore new research avenues
and bring new partners and young minds to the search for an HIV
vaccine. We  should challenge the way  we move products through
the vaccine development pipeline, which more often than not, have
ended up in disappointment after efﬁcacy trials are conducted. We
need to create incentives for the pharmaceutical industry, includ-
ing developing country vaccine manufacturers. We need to enroll
the full participation of people from developing countries, not only
as vaccine testing sites, but as full partners who  stand to beneﬁt the
most from an HIV vaccine. We need to have serious discussions with
regulatory agencies to streamline a renewed effort to develop an
HIV vaccine. And, very importantly, we need to convince national
authorities, funders, and policy makers that the development of an
HIV vaccine is not only a challenging scientiﬁc question, but rather
a critical public health priority.
How soon we will have an HIV vaccine will depend on the deci-
sion we  make today. The ﬁeld needs to approach the challenge with
a sense of urgency, recognizing that a vaccine would be essential
for the ultimate control of the pandemic, especially in the poo-
rest countries of the world, while complementing other prevention
strategies [369].
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